Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC) is a low-differentiated neuroendocrine tumor with rapid growth, early metastasis and sensitivity to radiotherapy chemotherapy. It highly recurrence rate. And there lacking effective treatment now. As an active research direction at present, anti-angiogenic drugs are not only widely used in non-small cell lung cancer other tumors, but also have certain effects small combined one of the methods for cancer, related rare, still inadequacy, such as side can be tolerated, timing accurately assessed. This article will briefly describe progress chemotherapy first-line extensive cancer.